Anti-bacterial monoclonal antibodies: next generation therapy against superbugs
The DOI matches its Crossref record; 122 of the 122 references it cites were found in a registry or an index.
Abstract
Prior to the nineteenth century, infectious disease was one of the leading causes of death. Human life expectancy has roughly doubled over the past century as a result of the development of antibiotics and vaccines. However, the emergence of antibiotic-resistant superbugs brings new challenges. The side effects of broad-spectrum antibiotics, such as causing antimicrobial resistance and destroying the normal flora, often limit their applications. Furthermore, the development of new antibiotics has lagged far behind the emergence and spread of antibiotic resistance. On the other hand, the genome complexity of bacteria makes it difficult to create effective vaccines. Therefore, novel therapeutic agents in supplement to antibiotics and vaccines are urgently needed to improve the treatment of infections. In recent years, monoclonal antibodies (mAbs) have achieved remarkable clinical success in a variety of fields. In the treatment of infectious diseases, mAbs can play functions through multiple mechanisms, including toxins neutralization, virulence factors inhibition, complement-mediated killing activity, and opsonic phagocytosis. Toxins and bacterial surface components are good targets to generate antibodies against. The U.S. FDA has approved three monoclonal antibody drugs, and there are numerous candidates in the preclinical or clinical trial stages. This article reviews recent advances in the research and development of anti-bacterial monoclonal antibody drugs in order to provide a valuable reference for future studies in this area. KEY POINTS: • Novel drugs against antibiotic-resistant superbugs are urgently required • Monoclonal antibodies can treat bacterial infections through multiple mechanisms • There are many anti-bacterial monoclonal antibodies developed in recent years and some candidates have entered the preclinical or clinical stages of development.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“More selective alternatives to antibiotics, such as targeted phage therapy or monoclonal antibodies against specific bacteria (Gaborieau et al., 2024; Wang et al., 2022), may also minimize dysbiosis and sustain ICB efficacy.”
From Microbiota-centered interventions to boost immune checkpoint blockade therapies (2025) · cites this paper as Wang et al., 2022
Citations
Cites
Phagocytosis of Microbes: Complexity in Action
Underhill, D. M., & Ozinsky, A. (2002) · Annual Review of Immunology · doi:10.1146/annurev.immunol.20.103001.114744 · Cited by 1,124 · cited 1×
“Activation of complement receptors and FcRs can generate synergistic effects, which are also influenced by other antibody-independent signals, such as Toll-like receptor (TLR) signals (Underhill and Ozinsky 2002).”
BackgroundNovel antibody-antibiotic conjugate eliminates intracellular S. aureus
Lehar, S. M., Pillow, T., Xu, M., Staben, L., Kajihara, K. K., Vandlen, R., DePalatis, L., Raab, H., Hazenbos, W. L., Hiroshi Morisaki, J., et al. (2015) · Nature · doi:10.1038/nature16057 · Cited by 838
Infections of People with Complement Deficiencies and Patients Who Have Undergone Splenectomy
Ram, S., Lewis, L. A., & Rice, P. A. (2010) · Clinical Microbiology Reviews · doi:10.1128/cmr.00048-09 · Cited by 405
Raxibacumab for the Treatment of Inhalational Anthrax
Migone, T.-S., Subramanian, G. M., Zhong, J., Healey, L. M., Corey, A., Devalaraja, M., Lo, L., Ullrich, S., Zimmerman, J., Chen, A., et al. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0810603 · Cited by 294
A multifunctional bispecific antibody protects against Pseudomonas aeruginosa
DiGiandomenico, A., Keller, A. E., Gao, C., Rainey, G. J., Warrener, P., Camara, M. M., Bonnell, J., Fleming, R., Bezabeh, B., Dimasi, N., et al. (2014) · Science Translational Medicine · doi:10.1126/scitranslmed.3009655 · Cited by 277
Moayeri, M., Leppla, S. H., Vrentas, C., Pomerantsev, A. P., & Liu, S. (2015) · Annual Review of Microbiology · doi:10.1146/annurev-micro-091014-104523 · Cited by 262
Satlin, M. J., Chen, L., Patel, G., Gomez-Simmonds, A., Weston, G., Kim, A. C., Seo, S. K., Rosenthal, M. E., Sperber, S. J., Jenkins, S. G., et al. (2017) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.02349-16 · Cited by 252
Di Bella, S., Ascenzi, P., Siarakas, S., Petrosillo, N., & Di Masi, A. (2016) · Toxins · doi:10.3390/toxins8050134 · Cited by 248
Mishra, M., Byrd, M. S., Sergeant, S., Azad, A. K., Parsek, M. R., McPhail, L., Schlesinger, L. S., & Wozniak, D. J. (2012) · Cellular Microbiology · doi:10.1111/j.1462-5822.2011.01704.x · Cited by 243
ADAM10 Mediates Vascular Injury Induced by Staphylococcus aureus α-Hemolysin
Powers, M. E., Kim, H. K., Wang, Y., & Bubeck Wardenburg, J. (2012) · The Journal of Infectious Diseases · doi:10.1093/infdis/jis192 · Cited by 199
Cited by
Alternative therapeutic strategies to treat antibiotic-resistant pathogens
MacNair, C. R., Rutherford, S. T., & Tan, M.-W. (2024) · Nature Reviews Microbiology · doi:10.1038/s41579-023-00993-0 · Cited by 276
“…targeting the Staphylococcus aureus α-toxin failed to reduce the infection in pneumonia 61 ; however, additional toxin-neutralizing or virulence factor-neutralizing mAbs are in various stages of clinical development, highlighting the perceived utility of these molecules to help patients 53,62,63 .”
Antibody–Antimicrobial Conjugates for Combating Antibiotic Resistance
Yu, L., Shang, Z., Jin, Q., Chan, S. Y., Hong, W., Li, N., & Li, P. (2022) · Advanced Healthcare Materials · doi:10.1002/adhm.202202207 · Cited by 41
Qin, J., Li, J., Pei, H., Li, Q., Cheng, D., Zhou, J., Pei, G., Wang, Y., & Liu, F. (2024) · Environmental Technology & Innovation · doi:10.1016/j.eti.2024.103649 · Cited by 32
Nanomaterials as multimodal photothermal agents (PTAs) against ‘Superbugs’
Roy, S., Roy, J., & Guo, B. (2023) · Journal of Materials Chemistry B · doi:10.1039/d2tb02396b · Cited by 31
Esposito, S., Amirthalingam, G., Bassetti, M., Blasi, F., Rosa, F. G. D., Halasa, N., Hung, I. F., Osterhaus, A. D. M. E., Tan, T. Q., Torres, J. P., et al. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1162342 · Cited by 36
Metadata
- Authors
- Wang, H., Chen, D., & Lu, H.
- Affiliations
- Shanghai Jiao Tong University (CN)
- Corresponding author
- Lu, Huili
- Venue
- Applied Microbiology and Biotechnology
- Published
- 2022-06
- Volume
- 106
- Issue
- 11
- Pages
- 3957-3972
- ISSN
- 0175-7598 (ISSN-L)
- 1432-0614
- OpenAlex
- W4281685120
- Cited by
- 45
- References
- 122
- Citations by year
- 2026: 11 · 2025: 11 · 2024: 12 · 2023: 8 · 2022: 3
- FWCI
- 1.44
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springernature.com/gp/researchers/text-and-data-mining (tdm)
- www.springernature.com/gp/researchers/text-and-data-mining (vor)
- Locations
- Applied Microbiology and Biotechnology (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Life Sciences › Immunology and Microbiology › Immunology › Monoclonal and Polyclonal Antibodies Research
- Health Sciences › Medicine › Microbiology (medical) › Antibiotic Resistance in Bacteria
- Health Sciences › Medicine › Infectious Diseases › Antibiotic Use and Resistance
- Keywords
- antibiotic resistance, bacterial toxins, virulence factor inhibition, complement-mediated killing, opsonic phagocytosis, bacterial surface components, antibiotic therapy
- MeSH terms
- Anti-Bacterial Agents, Antibodies, Bacterial, Antibodies, Monoclonal, Bacteria, Bacterial Infections, Humans
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Anti-bacterial monoclonal antibodies: next generation therapy against superbugs. https://app.cochat.ai/papers/10.1007/s00253-022-11989-w
- The paper
- Wang, H., Chen, D., & Lu, H. (2022). Anti-bacterial monoclonal antibodies: next generation therapy against superbugs. Applied Microbiology and Biotechnology. https://doi.org/10.1007/s00253-022-11989-w
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.